Evaluation of efficacy and safety of Purim Tablets in chronic dermatitis, with special reference to atopic dermatitis

Dermatitis is a commonly encountered skin inflammation with variable etiology and clinical presentation. Available treatment options for dermatitis management have a major drawback of failure in prevently high recurrence and chronic dermatosis are characterized by recurrent exacerbations and remissions. This study was planned to evaluate the clinical efficacy and shortand long-term safety of Purim tablets in chronic dermatitis, with special reference to atopic dermatitis. This was an open non-comparative clinical trial and total fifty patients, who were refractory to conventional treatment and who were willing to give informed consent, were included in the study. Pregnant and lactating women, children below 14 years of age, patients with severe systemic illness and patients with genetic disorders were excluded from the study. At the initial visit, a detailed medical history, with special emphasis on family history of atopy, history of known contacts and treatment history was obtained from all patients. Duration of symptoms, onset status, recurrence, anatomical distribution, initiation of lesion, pain and presence of any additional signs was noted. The details of present episode were recorded in terms of onset, progression of the lesion, relieving factors and seasonal exacerbation. The local examination included details of the pattern and morphology of the lesion. Each symptom was given equal weightage on a specially designed score scale and the total score was calculated before and after the drug treatment. All the included patients were advised to consume Purim tablets, at a dose of 2 tablets, twice daily, for a period of six